AZTR

Azitra, Inc. (AZTR) Q1 2025 Filing Summary

Business Context and Reporting Period

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing novel therapeutics for precision dermatology using genetically engineered microbes. The company operates as a single segment and is currently in the pre-commercialization phase with no product revenue. This report covers the quarterly period ended March 31, 2025.

Key Financial Metrics

Operating Expenses: Total operating expenses were $3.1 million, comprised of $1.85 million in General and Administrative (G&A) costs and $1.25 million in Research and Development (R&D).

Cash Flow: Net cash used in operating activities was $3.07 million. Net cash provided by financing activities was $1.75 million, primarily from follow-on public offerings in January and February 2025.

Material Changes vs. Prior Period

• Net Loss: Increased by approximately 5% ($135,470) compared to Q1 2024, driven by higher G&A expenses.
• G&A Expenses: Increased 24% to $1.85 million due to higher accounting fees, legal fees, public relations, and consultant costs.
• R&D Expenses: Decreased 15% to $1.25 million, primarily due to reduced Chemistry, Manufacturing, and Controls (CMC) costs and consultant fees, partially offset by increased clinical costs for the ATR-04 program.
• Other Income: Interest income increased significantly to $37,164 from $7,609. The gain from the change in fair value of warrants decreased to $143 from $28,255 in the prior year.
• Capital Structure: The company completed two follow-on offerings in Q1 2025 (January and February), raising approximately $1.75 million in net proceeds. Outstanding common shares increased from 7.6 million to 15.0 million during the quarter.

Outlook, Risks, and Management Commentary

• Going Concern: Management has identified substantial doubt about the company's ability to continue as a going concern for twelve months from the filing date. The company has an accumulated deficit of $60.6 million and expects to incur additional losses. It will require significant additional funding to complete product development.
• Financing Needs: The company plans to raise funds through equity and/or debt financing. There is no assurance that such financing will be available on commercially reasonable terms.
• Clinical Pipeline:
  • ATR-12: Phase 1b trial for Netherton syndrome; first patient dosed in August 2024. Initial safety results expected in H1 2025.
  • ATR-04: Phase 1/2 trial for EGFRi-associated rash; Fast Track designation received. First patient dosing expected in H1 2025.
  • ATR-01: Lead optimization and IND-enabling studies planned for 2025 to support an IND filing in early 2026.
• Stock Split: Stockholders approved a potential reverse split (ratio 1:2 to 1:7) in February 2025 to maintain NYSE American compliance. The Board is still evaluating the exact ratio and timing.
• Internal Controls: Management identified a material weakness in disclosure controls and procedures related to a lack of adequate segregation of accounting functions.
• Subsequent Events: On April 24, 2025, the company entered into a Purchase Agreement with Alumni Capital LP for up to $20 million in equity. Initial purchases totaling approximately $401,000 in gross proceeds were made in May 2025.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $3.2 million cash balance against the projected burn rate of ~$3.1 million per quarter.
• Financing Execution: Monitor the execution of the $20 million Purchase Agreement with Alumni Capital LP and the status of the potential reverse stock split.
• Clinical Milestones: Track the timing of initial safety data readouts for ATR-12 and ATR-04, expected in the first half of 2025.
• Internal Controls: Assess the remediation plan for the material weakness in segregation of accounting duties.
• Dilution Risk: Review the impact of recent and potential future equity issuances on existing shareholder ownership.